LBA vs LC-MS/MS

LBA has been considered the gold standard for bioanalytical qualitative and quantitative analysis of ADA, NAb, TAb and total ADC. It offers low-cost equipment, high throughput and historically greater sensitivity at the lower limit of detection. In contrast, LC-MS/MS analysis offers greater specificity and selectivity, faster assay development, higher order of magnitude (>3 orders), the ability to multiplex and is considered gold standard for small molecule analysis. Increasingly, Hybrid LC-MS/MS is being viewed as a tool to increase the understanding of therapeutics with highly specified quantitative analysis due to its offering of time-effective and versatile bioanalytical solutions. If properly designed, hybrid LC-MS/MS assays have the potential to support biotherapeutics development all the way up to clinical trials.

This feature was produced in association with ICON Plc.